21st Century Oncology Announces Postponement of Initial Public Offering

FORT MYERS, Fla., May 21, 2014 (GLOBE NEWSWIRE) -- 21st Century Oncology Holdings, Inc. ("21st Century Oncology" or "the Company") today announced that due to unfavorable current market conditions it has postponed its initial public offering of shares of its common stock and its concurrent public offering of shares of its Series A mandatory convertible junior non-voting preferred stock. The Company's registration statement on Form S-1, as filed with the Securities and Exchange Commission (the "Commission"), has not been withdrawn and the Company will continue to evaluate the timing for the offerings as market conditions develop.

The registration statement on Form S-1 relating to these securities has been filed with the Commission but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About 21st Century Oncology Holdings, Inc.

21st Century Oncology Holdings, Inc. is the largest global, physician led provider of Integrated Cancer Care Services. The Company offers a comprehensive range of cancer treatment services, focused on delivering academic quality, cost-effective patient care in personal and convenient settings. The Company operates 185 treatment centers, including 150 centers located in 16 U.S. states. The Company also operates 35 centers located in six countries in Latin America. The Company holds market leading positions in most of its domestic local markets and abroad.

CONTACT: Bryan J. Carey President and CFO 239-931-7281 bcarey@21co.com Investors: Nick Laudico The Ruth Group 646-536-7030 nlaudico@theruthgroup.comSource:21st Century Oncology Holdings, Inc.